Impact of waning immunity against SARS-CoV-2 severity exacerbated by vaccine hesitancy

Chadi M. Saad-Roy, Sinead E. Morris, Mike Boots, Rachel E. Baker, Bryan L. Lewis, Jeremy Farrar, Madhav V. Marathe, Andrea L. Graham, Simon A. Levin, Caroline E. Wagner, C. Jessica E. Metcalf, Bryan T. GrenfellPLOS Computational Biology 2024 · DOI · OpenReview

TL;DR

This paper uses mathematical modeling to explore how waning immunity and vaccine hesitancy interact to shape the trajectory of SARS-CoV-2 severity. The findings highlight that vaccine hesitancy can significantly undermine the benefits of even robust vaccines, leading to persistent outbreaks of severe disease, especially if vaccine-hesitant individuals are more transmissible.

What Problem Does This Paper Address?

The COVID-19 pandemic has presented a complex challenge in understanding and managing its long-term impact. While vaccines have been instrumental in reducing severe illness and hospitalizations, several uncertainties remain. These include the duration of immunity conferred by infection or vaccination, and how this immunity wanes over time. Furthermore, the heterogeneous uptake of vaccines, driven by factors like hesitancy, creates complex population-level immune landscapes. This paper aims to disentangle these factors by investigating how waning severity-blocking immunity, combined with varying vaccination rates and vaccine hesitancy, influences the medium-term immuno-epidemiological dynamics of SARS-CoV-2. Understanding these interactions is crucial for predicting future disease burdens and informing public health strategies.

Methods

The authors employ a compartmental mathematical modeling framework, extending a previously developed SIR(S) model. This model tracks different states of individuals within a population, including susceptible, infected (primary and secondary), recovered (fully immune), and vaccinated. Crucially, the model incorporates compartments for individuals with "waned severity-blocking immunity" and those infected after this waning occurs. The model allows for the simulation of varying rates of vaccination, waning of both transmission-blocking and severity-blocking immunity (natural and vaccinal), and different levels of relative susceptibility to infection after immunity wanes. They also extend the model to include a group of vaccine-hesitant individuals who mix homogeneously with vaccine adopters. The analysis focuses on medium-term outcomes, examining infection levels and the characteristics of these infections over several years.

Datasets

Not discussed in the paper. The study relies on a mathematical modeling framework and does not analyze empirical datasets for training or evaluation.

Key Insights and Ideas

  • Waning immunity is a critical driver of future outbreaks: Even with vaccination, the gradual loss of immunity against severe disease can lead to recurrent waves of infection, particularly if immunity wanes quickly.
  • Vaccine hesitancy is a major hurdle: Heterogeneity in vaccine uptake, driven by hesitancy, can significantly blunt the impact of even highly effective and durable vaccines. This is because vaccine-adopters are frequently re-vaccinated, while hesitant individuals rely solely on infection for immunity, leading to a larger pool of susceptible individuals with waned immunity.
  • Transmissibility of hesitant individuals amplifies the problem: If vaccine-hesitant individuals are more transmissible, the negative impact of hesitancy is magnified, creating a steeper threshold for increased cumulative infections.
  • Durable vaccines are more effective with high uptake: While more durable vaccines can reduce uncertainties and disease burden, their full potential is realized only when combined with high vaccination rates and broad coverage.
  • Predicting infection from hospitalizations is challenging: The dynamics of waning severity-blocking immunity complicate efforts to infer infection levels from hospitalization data, underscoring the need for accurate estimates of immune parameters.

Key Results

  • Duration of immunity matters: Longer durations of severity-blocking immunity (both natural and vaccinal) generally lead to fewer infections with waned immunity.
  • Vaccination rate is key: Higher vaccination rates consistently reduce the fraction of individuals with waned severity-blocking immunity and the overall infection burden.
  • Heterogeneity's impact: In scenarios with significant vaccine hesitancy (e.g., 40-80% of the population), the benefits of more durable vaccines are substantially diminished. The cumulative number of infections in the "waned severity-blocking immunity" class can increase sharply beyond a certain threshold of vaccine hesitancy.
  • Transmissibility multiplier: An increase in the transmissibility of vaccine-hesitant individuals (e.g., 1.2x or 1.5x) significantly exacerbates the cumulative infections in the waned immunity class, especially in scenarios with faster waning of immunity.

Limitations and Future Work

The authors acknowledge several simplifying assumptions in their model:

  • Vaccine dosing regimes: The model assumes a constant rate of vaccination and that each subsequent vaccine confers similar immunity, neglecting the potential for multiple doses to build more robust immunity.
  • Accumulation of immunity: The model does not explicitly account for the potential accumulation of immunity (transmission-blocking or severity-blocking) after multiple exposures (infection or vaccination).
  • Time-dependent vaccination rates: The study uses constant vaccination rates, whereas real-world vaccination campaigns are often dynamic.
  • Homogeneous mixing: Interactions between vaccine-hesitant and vaccine-adopter groups are assumed to be homogeneous, which may not reflect real-world social structures.
  • Other heterogeneities: The model does not account for other important heterogeneities such as variations in transmission, age, or individual vulnerabilities.
  • Behavioral dynamics: The influence of human behavior, including adherence to nonpharmaceutical interventions (NPIs) and the dynamics of vaccine hesitancy itself, are not explicitly modeled.
  • Within-host dynamics and viral evolution: The model does not incorporate within-host viral dynamics or viral evolution, which could influence disease severity and immune escape.
  • Long COVID: The dynamics of Long COVID are not considered.

Future work suggested includes developing more complex models that incorporate these factors, utilizing detailed data from cohort studies, and exploring the interplay between behavioral dynamics and epidemiological outcomes. The authors also provide an interactive online application to explore a broad range of model scenarios.

Summary updated

Abstract

The SARS-CoV-2 pandemic has generated a considerable number of infections and associated morbidity and mortality across the world. Recovery from these infections, combined with the onset of large-scale vaccination, have led to rapidly-changing population-level immunological landscapes. In turn, these complexities have highlighted a number of important unknowns related to the breadth and strength of immunity following recovery or vaccination. Using simple mathematical models, we investigate the medium-term impacts of waning immunity against severe disease on immuno-epidemiological dynamics. We find that uncertainties in the duration of severity-blocking immunity (imparted by either infection or vaccination) can lead to a large range of medium-term population-level outcomes (i.e. infection characteristics and immune landscapes). Furthermore, we show that epidemiological dynamics are sensitive to the strength and duration of underlying host immune responses; this implies that determining infection levels from hospitalizations requires accurate estimates of these immune parameters. More durable vaccines both reduce these uncertainties and alleviate the burden of SARS-CoV-2 in pessimistic outcomes. However, heterogeneity in vaccine uptake drastically changes immune landscapes toward larger fractions of individuals with waned severity-blocking immunity. In particular, if hesitancy is substantial, more robust vaccines have almost no effects on population-level immuno-epidemiology, even if vaccination rates are compensatorily high among vaccine-adopters. This pessimistic scenario for vaccination heterogeneity arises because those few individuals that are vaccine-adopters are so readily re-vaccinated that the duration of vaccinal immunity has no appreciable consequences on their immune status. Furthermore, we find that this effect is heightened if vaccine-hesitants have increased transmissibility (e.g. due to riskier behavior). Overall, our results illustrate the necessity to characterize both transmission-blocking and severity-blocking immune time scales. Our findings also underline the importance of developing robust next-generation vaccines with equitable mass vaccine deployment.
BibTeX
@article{saadroy2024impact,
  author = {Chadi M. Saad-Roy and Sinead E. Morris and Mike Boots and Rachel E. Baker and Bryan L. Lewis and Jeremy Farrar and Madhav V. Marathe and Andrea L. Graham and Simon A. Levin and Caroline E. Wagner and C. Jessica E. Metcalf and Bryan T. Grenfell},
  title = {{Impact of waning immunity against SARS-CoV-2 severity exacerbated by vaccine hesitancy}},
  journal = {PLOS Computational Biology},
  year = {2024},
  doi = {10.1371/journal.pcbi.1012211},
}
Figure